BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. (BDSI), headquartered in the United States, is a pioneering biopharmaceutical company focused on developing and commercialising innovative therapeutics for patients with chronic pain and substance use disorders. Founded in 1997, BDSI has achieved significant milestones, including the successful launch of its flagship product, BELBUCA®, a buprenorphine film that offers a unique delivery system for pain management. Operating primarily in the biopharmaceutical industry, BDSI is dedicated to advancing its proprietary drug delivery technologies, which enhance the efficacy and safety of its products. With a strong market position, BDSI has garnered recognition for its commitment to improving patient outcomes and addressing unmet medical needs. The company continues to expand its portfolio, solidifying its role as a leader in the field of pain management and addiction treatment.
DitchCarbon Score
How does BioDelivery Sciences International, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
BioDelivery Sciences International, Inc.'s score of 35 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
BioDelivery Sciences International, Inc.'s reported carbon emissions
BioDelivery Sciences International, Inc., headquartered in the US, has not reported specific carbon emissions data for the most recent year. However, the company has established significant climate commitments aimed at reducing its carbon footprint. BioDelivery Sciences has set an ambitious interim target to achieve a 50% reduction in emissions across all scopes by 2030, with the baseline starting in 2023. This commitment aligns with their goal of reaching net zero emissions. It is important to note that emissions data may be cascaded from their parent company, Collegium Pharmaceutical, Inc., which could provide further insights into their overall environmental impact. As a current subsidiary, BioDelivery Sciences is part of a broader initiative to enhance sustainability practices within its corporate family. While specific emissions figures are currently unavailable, the company's proactive approach to setting reduction targets reflects a growing trend in the pharmaceutical industry towards greater accountability and climate action.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
BioDelivery Sciences International, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
